Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Trial Investigating the Concentration in the Blood of NN1250 in Children, Adolescents and Adults With Type 1 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2009-12-14
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 39
- Registration Number
- NCT01030926
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Hannover, Germany
A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes
Phase 1
Completed
- Conditions
- HealthyDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2017-07-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 84
- Registration Number
- NCT01028404
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Preference Study Between NovoFine® Autocover™ and a NovoFine® 8 mm Needle
Phase 4
Completed
- Conditions
- DiabetesDelivery SystemsHealthcare Professionals
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 78
- Registration Number
- NCT01024218
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, København, Denmark
Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-12-01
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 440
- Registration Number
- NCT01022762
An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)
Phase 1
Withdrawn
- Conditions
- InflammationSystemic Lupus Erythematosus
- Interventions
- Drug: placebo
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT01018238
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Lake Success, New York, United States
An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)
Completed
- Conditions
- Growth Hormone DisorderPituitary DwarfismHypopituitarism
- Interventions
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 22960
- Registration Number
- NCT01009905
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Plainsboro, New Jersey, United States
Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2009-11-06
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 447
- Registration Number
- NCT01009580
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Kocaeli, Turkey
A Trial Investigating the NN1250 Concentration-time Curve in Subjects With Various Degrees of Renal Impairment and in Subjects With Normal Renal Function
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT01006057
- Locations
- 🇭🇺
Novo Nordisk Investigational Site, Budapest, Hungary
Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 687
- Registration Number
- NCT01006291
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom
Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 Diabetics
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- Interventions
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 28
- Registration Number
- NCT01002768
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
© Copyright 2025. All Rights Reserved by MedPath